The Japanese Journal of Dermatology
Online ISSN : 1346-8146
Print ISSN : 0021-499X
ISSN-L : 0021-499X
Search
Advanced search
OR
Browse
Search
Volume 135, Issue 3
Displaying 1-12 of 12 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Obituary
Guidelines
Seminar for Medical Education
Erratum
Original Articles
  • Seven Cases of Scalp and Facial Dermatitis Caused by Cocamidopropyl Betaine, an Amphoteric Surfactant
    Shigeruko Iijima, Kayoko Matsunaga
    2025 Volume 135 Issue 3 Pages 625-636
    Published: March 20, 2025
    Released on J-STAGE: March 21, 2025
    DOIhttps://doi.org/10.14924/dermatol.135.625
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract

    Cocamidopropyl betaine (CAPB) is an amphoteric surfactant derived from coconut oil fatty acids; it is commonly used in shampoos. To identify the causes of persistent scalp and facial dermatitis, we conducted patch tests using the shampoos that the patients had used, along with CAPB-related compounds. The results confirmed that CAPB-related compounds in the shampoos were one of the causative factors for their dermatitis. In this report, we present seven cases (2 males and 5 females, aged 12 to 69 years, with disease durations ranging from 1.5 months to several years) in which scalp and facial dermatitis improved after switching to CAPB-free shampoos. Patch testing for CAPB has proven valuable in diagnosing shampoo-induced allergic contact dermatitis.

    View full abstract
    Download PDF (1645K)
  • Advanced Conjunctival Melanoma Treated with Systemic Therapy: A Case Series of Six Patients
    Akihiro Ishiguro, Kenichiro Mae, Masae Yoshida, Harutaka Seshimo, Rika ...
    2025 Volume 135 Issue 3 Pages 637-642
    Published: March 20, 2025
    Released on J-STAGE: March 21, 2025
    DOIhttps://doi.org/10.14924/dermatol.135.637
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract

    Conjunctival melanoma is extremely rare in Japan; only ten cases are reported annually. Owing to frequent recurrences and metastases, the prognosis is poor. We herein summarized six cases of advanced conjunctival melanoma treated with systemic therapy. Immune checkpoint inhibitors and a kinase inhibitor were chosen as the initial, systemic therapy in five and one patient, respectively. Three of the five patients showed improvement with the immune checkpoint inhibitors. The median overall survival from systemic therapy and the one-year overall survival rate were 15.5 months and 50%, respectively. Although mucosal melanomas tend to respond less well to systemic therapy than cutaneous melanomas do, conjunctival melanomas may respond as well as cutaneous ones.

    View full abstract
    Download PDF (572K)
Abstracts
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top